Artivion, Inc., a prominent company in cardiac and vascular surgery, has announced the release date for its third quarter 2025 financial results. The report will be made public on November 6, 2025, after the market closes.
On the same day, the company will conduct a teleconference call and live webcast at 16:30 ET to discuss the financial results. This session will feature a question-and-answer segment led by Pat Mackin, who serves as the Chairman, President, and Chief Executive Officer of Artivion.
To participate in the live teleconference, interested parties are encouraged to dial 201-689-8261 shortly before the start time. Following the event, a replay will be available approximately one hour later. This can be accessed by calling (toll free) 877-660-6853 or 201-612-7415, using the conference number 13755945.
For those who prefer online access, both the live webcast and subsequent replay can be found in the Investors section of the Artivion website at www.artivion.com, under the Webcasts & Presentations tab. Furthermore, a copy of the earnings press release, which will contain comprehensive financial and statistical data for the quarter and the full year, will also be available on the website.
About Artivion, Inc.
Based in suburban Atlanta, Georgia, Artivion is dedicated to developing innovative solutions for cardiac and vascular surgeons, particularly in the treatment of aortic diseases. The company’s key product categories include aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable human tissues. Artivion’s products are marketed and sold in over 100 countries worldwide, underscoring its significant global presence in the medical device industry.
For further details about Artivion and its offerings, visit their official website at www.artivion.com.
For additional inquiries, contact:
– Lance A. Berry, Executive Vice President, Chief Operating Officer & Chief Financial Officer at Artivion, phone: 770-419-3355
– Brian Johnston or Laine Morgan from Gilmartin Group LLC, phone: 332-895-3222, email: [email protected]
